![]() |
市場調查報告書
商品編碼
1439616
避孕藥 - 全球市場回顧、競爭格局、市場預測(2030)Contraceptive Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
2020年全球避孕藥具市場規模預計為313.2億美元,預計到2030年將達到418.4億美元,2024-2030年預測期間複合年增長率為6.71%。 對避孕藥具的需求主要是由於人們對意外懷孕和性傳染病(STD)相關併發症增加的認識的提高而推動的。 此外,婦女健康教育的不斷加強以及政府遏制人口快速增長的政策也推動了避孕藥具市場的成長。
避孕藥具市場動態
由於越來越多地採用避孕措施來防止意外懷孕,避孕藥具市場正在經歷顯著增長。 世界衛生組織(2019)發佈的一項研究顯示,全球每年有 7,400 萬名生活在低收入和中等收入國家的女性意外懷孕。 此外,《柳葉刀》(2020)發表的一項研究發現,從2015 年到2019 年,每年有1.21 億例意外懷孕,不確定性區間為80%,是全球最高的15 歲女性中,每1000 名49 歲女性中就有64 名意外懷孕。意外懷孕。 然而,根據全國家庭成長調查(2017-2019),美國15-49歲的女性中有65.3%使用避孕,而在目前情況下,最常用的避孕方法是,女性絕育(18.1%) )、口服避孕藥(14.0%)、LARC(10.4%)和男用保險套(8.4%)。 因此,大量人們使用避孕藥(如藥丸、長效避孕套和避孕套)來預防意外懷孕,可能會推動全球避孕藥市場的成長。
此外,避孕藥具使用率的快速增加也與政府針對婦女和兒童健康和福祉的大力宣傳和計劃有關。 透過使用有效的避孕方法控制生育能力是預防性保健的重要組成部分,可以理想地實現計劃懷孕和最佳健康。 基於對成功生殖過程的基本瞭解的避孕方法不僅對個人和家庭很重要,而且在人口控制中發揮著至關重要的作用。 這也是推動全球避孕藥具市場成長的主要因素。
此外,企業也正在增加基本避孕器具的產量。 例如,2022 年 1 月,Teva Pharmaceuticals API 宣佈推出 NuvaRing(一種雌激素和黃體素組合的荷爾蒙避孕藥)的仿製藥,供女性用於預防懷孕。 這些都是全球避孕藥具市場的驅動因素。
某些因素,例如與避孕藥具相關的副作用以及對某些避孕藥具的嚴格監管,可能會減緩避孕藥具市場的成長。
避孕藥具市場區隔分析
在避孕藥類型領域,預計女性避孕藥在預測期內將佔最大的市場佔有率。 這是因為女性避孕裝置的種類繁多,包括子宮內避孕器、陰道環、隔膜和皮下埋植劑。 此外,子宮內避孕器、避孕方法和女用保險套等避孕用品在全球女性中的顯著普及預計也將推動避孕用品市場的發展。 例如,根據聯合國經濟和社會事務部的數據,2019年全球有9.22億育齡婦女使用了避孕藥。
此外,新產品的核准也可能推動避孕藥具市場在預測期內快速成長。 例如,2018年,FDA批准了Annovera(醋酸賽孕酮和乙炔雌二醇陰道系統),這是一種針對育齡婦女的聯合激素避孕藥,用於預防懷孕並可全年使用。這是第一個可用的陰道環避孕裝置。 Annovera 是一種可重複使用的環形(環)、不可生物降解的柔性陰道系統,可在陰道內佩戴三週,然後在體外佩戴一週。
本報告提供了全球避孕藥具市場的研究和分析,包括市場規模和預測、驅動因素和挑戰以及公司和產品概況。
CONTRACEPTIVE DEVICES MARKET BY TYPE OF DEVICES (MALE CONTRACEPTIVE DEVICES AND FEMALE CONTRACEPTIVE DEVICES), BY PRODUCT TYPE (CONDOMS, DIAPHRAGMS, CERVICAL CAPS, VAGINAL RINGS, INTRA UTERINE DEVICES (IUD), AND OTHERS), AND BY GEOGRAPHY IS ANTICIPATED TO GROW AT A STEADY CAGR FORECAST till 2030 OWING TO RISING UNWANTED PREGNANCIES & SEXUALLY TRANSMITTED DISEASES AND RISING OVERPOPULATION
Global Contraceptive Devices Market was valued at USD 31.32 billion in 2020, growing at a CAGR of 6.71% during the forecast period from 2024 to 2030, to reach USD 41.84 billion by 2030. The demand for Contraceptive Devices is primarily attributed to the increasing number of unwanted pregnancies and the rising awareness regarding the complications associated with sexually transmitted diseases (STDs). In addition, rising education regarding female health and government policies to curb the burgeoning population growth are also the driving factors for contraceptive device market growth.
CONTRACEPTIVE DEVICES MARKET DYNAMICS:
The contraceptive Devices Market has notably increased due to the rise in the adoption of contraception to prevent unintended pregnancy. According to a study published by WHO 2019, globally, 74 million women living in low and middle-income countries have unintended pregnancies annually. Further, as per the study published in LANCET 2020, in 2015-19, there were 121.0 million unintended pregnancies annually with an 80% uncertainty interval, corresponding to a global rate of 64 unintended pregnancies per 1000 women aged 15-49 years. However, according to the National Survey of Family Growth, 2017-2019, 65.3% of women aged 15-49 in the United States were using contraception and the most common contraceptive methods used at present scenario were female sterilization (18.1%), oral contraceptive pills (14.0%), long-acting reversible contraceptives (LARCs) (10.4%), and the male condom (8.4%). Thus, the significant usage of contraception such as pills, LARC, and condoms among the population to prevent unintended pregnancies is likely to grow the Global Contraceptive Devices market.
Moreover, the surge in the usage of contraceptive devices is also associated with the robust government promotions and schemes for women and child health welfare. The ability to control fertility through the use of effective contraception is an essential component of preventive medicine, ideally resulting in planned pregnancies and optimal health. Contraceptive methods, based on a fundamental understanding of the processes of successful reproduction, are not only important for individuals and families but play an essential part in population regulation, this led to the promotion of family planning initiatives in developing and emerging nations by various governments. This is also a key factor contributing to the growth of the Global Contraceptive Devices market.
Additionally, the companies are also increasing their manufacturing of essential contraceptive devices products. For instance, In January 2022, Teva Pharmaceuticals API announced the availability of a generic version of NuvaRing ( an estrogen/progestin combination hormonal contraceptive) directed to be used by women to prevent pregnancy. These are the driving factors for the Global Contraceptive Devices market.
Certain factors such as side effects associated with the contraceptive devices, and stringent regulations for some of the contraceptive devices are likely to slow down the Contraceptive Devices market growth.
CONTRACEPTIVE DEVICES MARKET SEGMENT ANALYSIS:
Contraceptive Devices by Type of Devices (Male Contraceptive Devices and Female Contraceptive Devices), by Product Type (Condoms, Diaphragms, Cervical Caps, Vaginal Rings, Intrauterine Devices (IUD), and Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the Contraceptive Devices type of devices segment, female contraceptive devices are expected to hold the largest share in the market during the forecasted period. This is owing to the availability of a wide variety of female contraceptive devices such as intra uterine devices, vaginal rings, diaphragms, sub-dermal implants, and others. Furthermore, significant uptake of contraceptive devices such as IUDs, sterilization methods, female condoms among women all over the globe is also expected to propel the market for contraceptive devices. For instance, according to the United Nation's Department of Economics and Social Affairs, in 2019, 922 million women of reproductive age were contraceptive users, worldwide.
In addition, new product approvals are also likely to upsurge the contraceptive devices market during the forecasted period. For instance, in 2018, the FDA approved Annovera (segesterone acetate and ethinyl estradiol vaginal system), which is a combined hormonal contraceptive for women of reproductive age used to prevent pregnancy and is the first vaginal ring contraceptive that can be used for an entire year. Annovera is a reusable donut-shaped (ring), non-biodegradable, flexible vaginal system that is placed in the vagina for three weeks followed by one week out of the vagina.
Additionally, assistance from government bodies, such as NGOs, healthcare centers to educate women in rural regions of emerging economies such as India, China, and Brazil, among other developing nations regarding contraceptives, STDs, and unwanted pregnancy is expected to enhance the market potential in these countries. For instance, India's National Programme for Family Planning established in 1952, raises awareness among the population regarding policies to achieve population stabilization. Also, it promotes knowledge regarding reproductive health and reduces maternal, infant & child mortality and morbidity. Under this program, the public health sector provides various family planning services at various levels of the health system. Hence, all the above-mentioned factors are expected to drive the segment growth of the Contraceptive Devices market.
NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL CONTRACEPTIVE DEVICES MARKET:
North America is expected to dominate the overall Contraceptive Devices market during the forecast period. This domination is due to the rising prevalence of STDs, increasing healthcare expenditure, and improved healthcare infrastructure, among others.
Further, In the United States, the risk of being affected by a sexually transmitted disease is increasing dramatically due to the increase in unprotected sex and decreased condom use among vulnerable groups, including young people and gay and bisexual men, as per the CDC, 2019 data. This indicates that most Americans are likely to be affected by the sexually transmitted disease, in the coming decades. This situation is giving rise to a critical need for contraceptive devices for the prevention of transmission of STDs.
According to the Centre for Disease Control and Prevention (CDC), in 2018, 1 in 5 people in the U.S. had a sexually transmitted infection (STI). The prevalence of STIs in the United States was nearly 68 million infections in 2018 and 26 million new STI cases were reported. The CDC data also indicated that nearly half of all new STI infections occur among the nation's youth, with 45.5% of all new STIs were among young people ages 15-24 in 2018.
Moreover, increasing U.S. government support and funding to improve family planning and reproductive health (FP/RH) is also likely to drive the contraceptive devices market. For instance, in the year 2019, as per the Global Health Policy data, total U.S. funding for FP/RH, which includes the U.S. contribution to the United Nations Population Fund (UNFPA), was USD 608 million in FY 2019, up from USD 425 million in FY 2006. Thus, such an increase in funding is anticipated to stimulate the Contraceptive Devices market.
However, Europe and Asia-Pacific region have the future potential growth for the Global Contraceptive Devices. This is due to the rising burden of the population in the Asian countries and European countries also. The urgent need for family planning to curb the expanding population, various technological advancements, rising public awareness regarding reversible and cost-effective contraceptive measures, and emerging of local players in the specific regions is likely to boost the Contraceptive Devices market.
CONTRACEPTIVE DEVICES MARKET KEY PLAYERS:
Some of the key market players operating in the Contraceptive Devices market include Bayer Healthcare, Cooper Surgical Inc., Teva Pharmaceutical Industries Ltd, Reckitt Benckiser, FemCap Inc., The Female Health Company, Meril Life Sciences, Pregna International, and others.
RECENT DEVELOPMENTAL ACTIVITIES IN THE CONTRACEPTIVE DEVICES MARKET:
In February 2020, Agile Therapeutics, Inc received the US FDA approval for Twirla® (levonorgestrel and ethinyl estradiol) transdermal system which is a new weekly contraceptive patch delivering a 30 mcg daily dose of estrogen and 120 mcg daily doses of progestin.
In January 2020, Bayer AG and Dare Bioscience, Inc., a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health, entered into a licensing agreement under which Bayer may commercialize Dare's investigational contraceptive product, Ovaprene® in the United States once approved by the FDA.
KEY TAKES AWAY FROM THE CONTRACEPTIVE DEVICES MARKET REPORT STUDY
TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS CONTRACEPTIVE DEVICES MARKET REPORT STUDY
FREQUENTLY ASKED QUESTIONS FOR CONTRACEPTIVE DEVICES MARKET:
What are Contraceptive Devices?
Contraceptive devices are used for birth control by preventing unwanted pregnancies. Devices such as condoms, vaginal rings, IUDs are among a few of the contraceptive devices available in the market. Apart from preventing unintended pregnancies some of the contraceptive devices are also used as a prevention of sexually transmitted diseases.
What is the market for Global Contraceptive Devices?
Global Contraceptive Devices Market was valued at USD 31.32 billion in 2020, growing at a CAGR of 6.71% during the forecast period from 2024 to 2030, to reach USD 41.84 billion by 2030.
What are the drivers for Global Contraceptive Devices?
The major factors driving the demand for Contraceptive Devices are the rising concern of overpopulation in many countries, the increasing number of unintended pregnancies, and complications associated with STDs. Also, rising government initiatives for raising awareness regarding contraception are a driving factor in low-income and developing countries.
What are the key players operating in Global Contraceptive Devices Market?
Some of the key market players operating in the Contraceptive Devices market include Bayer Healthcare, Cooper Surgical Inc., Teva Pharmaceutical Industries Ltd, Reckitt Benckiser, FemCap Inc., The Female Health Company, Meril Life Sciences, Pregna International, and others.
What regions have the highest share in the Contraceptive Devices market?
North America is projected to dominate the overall Contraceptive Devices market during the forecast period, 2024-2030 due to the rising prevalence of STDs, increasing healthcare expenditure, and improved healthcare infrastructure, among others.